Research Summaries

Obinutuzumab Controls Growth of Slow-Growing Non-Hodgkin Lymphoma

ASCO Annual Meeting
May 30, 2015

In an ongoing study, researchers found that adding a new targeted therapy to chemotherapy controls non-Hodgkin lymphoma (NHL) growth for more than twice as long as only chemotherapy. The patients who participated in this study had indolent, or slow-growing, NHL. The standard first treatment for this common type of NHL is a combination of bendamustine (Treanda) and rituximab (Rituxan). For most patients, rituximab eventually stops working to control NHL growth.

New Treatment, Pacritinib, Helps Ease Myelofibrosis Symptoms

ASCO Annual Meeting
May 30, 2015

A recent study showed that the drug pacritinib works better for myelofibrosis than current treatments. Myelofibrosis is a rare blood cancer that develops when the bone marrow is unable to make enough blood cells. As a result, the spleen takes over the role of making blood cells but becomes quite enlarged. Patients also often experience tiredness, weakness, shortness of breath, fever, and weight loss because of an enlarged spleen. In addition, myelofibrosis turns into acute leukemia in about a third of patients with this disease.

Adding Ibrutinib to Standard Treatment Lowers the Risk of Dying from Chronic Lymphocytic Leukemia

ASCO Annual Meeting
May 30, 2015

In a large, ongoing study, researchers found that a combination of ibrutinib (Imbruvica) and standard treatment slows the growth of chronic lymphocytic leukemia (CLL) and lowers patients’ risk of dying from the disease. The standard treatment for CLL is usually a combination of bendamustine (Treanda) and rituximab (Rituxan), a regimen called BR.

Early Research Shows Potential of Pembrolizumab as Head and Neck Cancer Treatment

ASCO Annual Meeting
May 29, 2015

Results from a phase I clinical trial show that pembrolizumab (Keytruda) is able to shrink head and neck cancer that has spread to other parts of the body or come back after treatment. These findings suggest that immunotherapy may fill a large unmet need for better treatments for recurrent and advanced head and neck cancer.

Nivolumab Shows Promise as a Treatment Option for Advanced Liver Cancer

ASCO Annual Meeting
May 29, 2015

In an early-stage study, nivolumab (Opdivo) has shown encouraging results as a treatment for advanced liver cancer. Liver cancer is the leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. People diagnosed with advanced liver cancer especially need new treatment options, as there is currently only one drug approved by the U.S. Food and Drug Administration (FDA).

Adding Immune-Based Drug to Standard Treatment Controls the Growth of Multiple Myeloma for Longer

ASCO Annual Meeting
May 13, 2015

As part of an ongoing study, researchers found that a new immune-based treatment controlled the growth of multiple myeloma for longer than standard treatment. This new treatment, elotuzumab, works in two different ways to treat myeloma. It is able to directly target multiple myeloma cells and boost a part of the immune system that helps control the growth of cancer cells.

Adding Docetaxel to Standard Prostate Cancer Treatment Lengthens Lives

ASCO Annual Meeting
May 13, 2015

A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.

Pages

Subscribe to RSS - Research Summaries